T cell receptor-based immunotherapy: a review.
- Author:
Yuan CHEN
1
;
George F GAO
1
;
Shuguang TAN
2
Author Information
- Publication Type:Journal Article
- Keywords: T cell engager; T cell receptor; T cell receptor-engineered T cell; immunotherapy
- MeSH: Humans; Receptors, Antigen, T-Cell/metabolism*; T-Lymphocytes/metabolism*; Neoplasms/metabolism*; Immunotherapy; Antigens, Neoplasm
- From: Chinese Journal of Biotechnology 2023;39(10):4004-4028
- CountryChina
- Language:Chinese
- Abstract: T cells play central roles in anti-tumor immune responses. Immune checkpoint therapy, which is based on modulation of T cell reactivity, has achieved breakthrough in clinical treatment of multiple tumors. Moreover, adoptive T cell therapy, which includes mainly genetically engineered T cells, has shown substantial treatment efficacy in hematoma. Immune therapy has tremendously changed the scenario of clinical tumor treatment and become critical strategies for treating multiple tumors. T cell receptor (TCR) is the fundamental molecule responsible for the specificity of T cell recognition. TCRs could recognize peptides, which are derived from intracellular or extracellular tumor antigens, presented by major histocompatibility complex (MHC) and are therefore highly sensitive to low antigen level. Thereby, TCRs are broadly recognized as promising molecules for the development of anti-tumor drugs. The approval of the first TCR drug in 2022 has initiated a new era for TCR-based therapeutics and since then, multiple TCR drugs have shown substantial treatment efficacy in multiple tumors. This review summarizes the progress of TCR-based immune therapeutic strategies, including T cell receptor-engineered T cell (TCR-T), TCR-based protein drugs, and other cell therapies based on TCR signaling, providing useful information for future design of immune therapeutics based on TCR.
